NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mirvie

Mirvie

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.mirvie.com/

Last Round

Series C

Sep 11, 2025

Est. Valuation

$155M

Total Funding Raised

$124.6M

Company Overview

Mirvie is a biotechnology company that provides a medical diagnostic platform aimed at enhancing pregnancy safety through predictive tests and therapeutic solutions for effective pregnancy management.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices, Clinical Trials

Business Model

B2B2C

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

liquid biopsycell-free RNAcfRNApreeclampsia predictionfemtechpregnancy complicationsprenatal diagnostic testmaternal healthpredictive diagnosticsclinical decision supportFDA breakthrough devicemolecular signaturesdirect-to-consumer diagnosticsDTC testingprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mirvie Comparables

Compare Mirvie with similar companies based on industry and business-model similarity.

Mirvie comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sera Prognostics Inc.
77%
Trinity Biotech plc
77%
NX Prenatal Inc.
76%

Mirvie Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 11, 2025
Series CAug 1, 2025
GrantAug 2, 2023
DebtMay 17, 2022
Series BMay 17, 2022
Series A
Apr 27, 2021

Key People

Founding team and executive leadership

Maneesh Jain

CEO & Co-founder

Founding Team

Manfred Lee

Chief Operating Officer

Executive Team

Mirvie Investors

Notable investors and investment history

Mirvie investors
InvestorRounds
GVSeries B
Khosla VenturesSeries B, Series A
PortfoliaSeries C
Gates FoundationGrant
General CatalystSeries B
Foresite CapitalSeries B
The Bill & Melinda Gates Foundation TrustGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2025

    $30M Series C round completed.

  • May 14, 2025

    Launched Encompass, a preeclampsia risk prediction and prevention tool.

Mirvie Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mirvie Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mirvie's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range41
Year Founded2018
Last FundingSep 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.